Literature DB >> 32929218

TYK2 licenses non-canonical inflammasome activation during endotoxemia.

Andrea Poelzl1,2, Caroline Lassnig1,2, Simone Tangermann3, Dominika Hromadová1, Ursula Reichart4, Riem Gawish1, Kristina Mueller1, Richard Moriggl1, Andreas Linkermann5, Martin Glösmann4, Lukas Kenner3, Mathias Mueller1,2, Birgit Strobl6.   

Abstract

The non-canonical inflammasome is an emerging crucial player in the development of inflammatory and neurodegenerative diseases. It is activated by direct sensing of cytosolic lipopolysaccharide (LPS) by caspase-11 (CASP11), which then induces pyroptosis, an inflammatory form of regulated cell death. Here, we report that tyrosine kinase 2 (TYK2), a cytokine receptor-associated kinase, is a critical upstream regulator of CASP11. Absence of TYK2 or its kinase activity impairs the transcriptional induction of CASP11 in vitro and in vivo and protects mice from LPS-induced lethality. Lack of TYK2 or its enzymatic activity inhibits macrophage pyroptosis and impairs release of mature IL-1β and IL-18 specifically in response to intracellular LPS. Deletion of TYK2 in myeloid cells reduces LPS-induced IL-1β and IL-18 production in vivo, highlighting the importance of these cells in the inflammatory response to LPS. In support of our data generated with genetically engineered mice, pharmacological inhibition of TYK2 reduced LPS-induced upregulation of CASP11 in bone marrow-derived macrophages (BMDMs) and of its homolog CASP5 in human macrophages. Our study provides insights into the regulation of CASP11 in vivo and uncovered a novel link between TYK2 activity and CASP11-dependent inflammation.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32929218      PMCID: PMC7862449          DOI: 10.1038/s41418-020-00621-x

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   12.067


  69 in total

Review 1.  Selective Tyk2 inhibitors as potential therapeutic agents: a patent review (2015-2018).

Authors:  Xingrui He; Xiabin Chen; Hancheng Zhang; Tian Xie; Xiang-Yang Ye
Journal:  Expert Opin Ther Pat       Date:  2019-01-22       Impact factor: 6.674

2.  Two rare disease-associated Tyk2 variants are catalytically impaired but signaling competent.

Authors:  Zhi Li; Milica Gakovic; Josiane Ragimbeau; Maija-Leena Eloranta; Lars Rönnblom; Frédérique Michel; Sandra Pellegrini
Journal:  J Immunol       Date:  2013-01-28       Impact factor: 5.422

3.  Kinase Inactive Tyrosine Kinase (Tyk2) Supports Differentiation of Brown Fat Cells.

Authors:  Vidisha Raje; Marta Derecka; Marc Cantwell; Jeremy Meier; Karol Szczepanek; Jennifer D Sisler; Birgit Strobl; Ana Gamero; Thurl E Harris; Andrew C Larner
Journal:  Endocrinology       Date:  2017-01-01       Impact factor: 4.736

Review 4.  Animal models of sepsis: setting the stage.

Authors:  Jon A Buras; Bernhard Holzmann; Michail Sitkovsky
Journal:  Nat Rev Drug Discov       Date:  2005-10       Impact factor: 84.694

Review 5.  The inflammatory response in sepsis.

Authors:  Markus Bosmann; Peter A Ward
Journal:  Trends Immunol       Date:  2012-10-02       Impact factor: 16.687

6.  Tyrosine kinase 2 is not limiting human antiviral type III interferon responses.

Authors:  Sebastian Fuchs; Petra Kaiser-Labusch; Julia Bank; Sandra Ammann; Anja Kolb-Kokocinski; Christine Edelbusch; Heymut Omran; Stephan Ehl
Journal:  Eur J Immunol       Date:  2016-10-05       Impact factor: 5.532

Review 7.  Tyrosine kinase 2 - Surveillant of tumours and bona fide oncogene.

Authors:  Nicole R Leitner; Agnieszka Witalisz-Siepracka; Birgit Strobl; Mathias Müller
Journal:  Cytokine       Date:  2015-11-26       Impact factor: 3.861

8.  Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis.

Authors:  Kim Papp; Kenneth Gordon; Diamant Thaçi; Akimichi Morita; Melinda Gooderham; Peter Foley; Ihab G Girgis; Sudeep Kundu; Subhashis Banerjee
Journal:  N Engl J Med       Date:  2018-09-11       Impact factor: 91.245

9.  In vivo tumor surveillance by NK cells requires TYK2 but not TYK2 kinase activity.

Authors:  Michaela Prchal-Murphy; Agnieszka Witalisz-Siepracka; Karoline T Bednarik; Eva Maria Putz; Dagmar Gotthardt; Katrin Meissl; Veronika Sexl; Mathias Müller; Birgit Strobl
Journal:  Oncoimmunology       Date:  2015-05-26       Impact factor: 8.110

10.  Human TYK2 deficiency: Mycobacterial and viral infections without hyper-IgE syndrome.

Authors:  Alexandra Y Kreins; Michael J Ciancanelli; Satoshi Okada; Xiao-Fei Kong; Noé Ramírez-Alejo; Sara Sebnem Kilic; Jamila El Baghdadi; Shigeaki Nonoyama; Seyed Alireza Mahdaviani; Fatima Ailal; Aziz Bousfiha; Davood Mansouri; Elma Nievas; Cindy S Ma; Geetha Rao; Andrea Bernasconi; Hye Sun Kuehn; Julie Niemela; Jennifer Stoddard; Paul Deveau; Aurelie Cobat; Safa El Azbaoui; Ayoub Sabri; Che Kang Lim; Mikael Sundin; Danielle T Avery; Rabih Halwani; Audrey V Grant; Bertrand Boisson; Dusan Bogunovic; Yuval Itan; Marcela Moncada-Velez; Ruben Martinez-Barricarte; Melanie Migaud; Caroline Deswarte; Laia Alsina; Daniel Kotlarz; Christoph Klein; Ingrid Muller-Fleckenstein; Bernhard Fleckenstein; Valerie Cormier-Daire; Stefan Rose-John; Capucine Picard; Lennart Hammarstrom; Anne Puel; Saleh Al-Muhsen; Laurent Abel; Damien Chaussabel; Sergio D Rosenzweig; Yoshiyuki Minegishi; Stuart G Tangye; Jacinta Bustamante; Jean-Laurent Casanova; Stéphanie Boisson-Dupuis
Journal:  J Exp Med       Date:  2015-08-24       Impact factor: 14.307

View more
  3 in total

Review 1.  How Pyroptosis Contributes to Inflammation and Fibroblast-Macrophage Cross-Talk in Rheumatoid Arthritis.

Authors:  Benjamin Demarco; Sara Danielli; Fabian A Fischer; Jelena S Bezbradica
Journal:  Cells       Date:  2022-04-12       Impact factor: 7.666

2.  MicroRNA-455-3p regulates proliferation and osteoclast differentiation of RAW264.7 cells by targeting PTEN.

Authors:  Xiaolu Zhang; Liangming Wang; Nianlai Huang; Yiqiang Zheng; Liquan Cai; Qingfeng Ke; Shiqiang Wu
Journal:  BMC Musculoskelet Disord       Date:  2022-04-09       Impact factor: 2.362

3.  Defining resistance and tolerance traits in Covid-19: towards a stratified medicine approach.

Authors:  C D Russell; S Clohisey Hendry
Journal:  QJM       Date:  2022-08-13
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.